SEC Form 4 · accession 0001562180-16-003828
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kimi Iguchi
Officer — CFO, Secretary and Treasurer
Period of report
Dec 8, 2016
Accepted (ET)
Dec 16, 2016 · 4:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $38.25 | Dec 8, 2016 | A | 14,400 | A | Dec 8, 2016 | Jan 23, 2025 | Common Stock | 14,400 | 68,000 | D |
Explanation of responses
- F1The securities awarded on 1/23/2015 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 5,000 shares of common stock vested on the one year anniversary of the Vesting Start Date with 15,000 shares vesting in 36 equal monthly installments thereafter. Options to purchase 48,000 shares of common stock vest periodically over four years from the grant date upon the company reaching certain milestone requirements, of which the performance criteria were met with the respect of 14,400 shares.